J&J’s psoriasis drug faces crowded market after US approval
J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.
X
J&J’s psoriasis drug faces crowded market after US approval
https://pharmaphorum.com/news/jj-psoriasis-us-approval/
dermatology
Novartis’ psoriasis drug gets label boost
New label shows Cosentyx is superior to J&J’s rival in long-term.
Cardiome antibiotic could reduce pressure on NHS
Xydalba allows patients to be treated and quickly discharged.
Valeant’s Siliq price undercuts rivals to offset black box warning
Siliq will be cheaper than rivals from Novartis and Eli Lilly.
FDA approves two biggest new drugs of 2017
Sales of MS and eczema drugs could top $4bn by 2022
Sanofi/Regeneron eczema data paves way for year’s biggest launch
Companies look to take on Pfizer after series of setbacks.
Shire fined $350m for skin product bribes
Settlement relates to investigation into Dermagraft sales.
Novartis’ Cosentyx beats J&J rival in psoriasis
Sales of dermatology drug are already mounting.